Anti-programmed cell death-ligand 1 antibody has been shown to target cancer cells by preventing the binding of the PD-L1 protein on cancer cells with the PD-1 receptor on T cells, which normally results in the silencing of the T cell response. This evidence concerns the gene CD274 and cancer.